Trastuzumab Deruxtecan Receives Accelerated Approval by FDA for HER2+ Breast Cancer

Fam-trastuzumab deruxtecan-nxki has been granted an accelerated approval by the FDA for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received at least 2 prior lines of anti–HER2-based regimens in the metastatic setting.

Read the full article here

Related Articles